BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
|
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -3.85 | -2.03 | -4.19 | -2.36 | -1.34 |
| CEPS(Rs) | -3.81 | -1.98 | -4.14 | -2.31 | -1.28 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | -5.33 | -1.48 | 0.55 | 4.74 | 7.10 |
| Tax Rate(%) | 25.28 | 9.64 | 25.18 | 28.11 | 21.43 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -36.02 | -6.34 | -24.45 | -15.56 | -11.14 |
| EBIT Margin(%) | -34.09 | -5.21 | -22.76 | -14.14 | -6.42 |
| Pre Tax Margin(%) | -49.92 | -12.36 | -28.37 | -21.25 | -8.82 |
| PAT Margin (%) | -37.30 | -11.17 | -21.23 | -15.28 | -6.93 |
| Cash Profit Margin (%) | -36.85 | -10.90 | -20.95 | -14.92 | -6.60 |
| Performance Ratios | |||||
| ROA(%) | -9.41 | -6.35 | -18.41 | -8.97 | -7.22 |
| ROE(%) | - | - | -158.64 | -39.93 | -17.00 |
| ROCE(%) | -25.63 | -8.08 | -73.05 | -21.87 | -10.70 |
| Asset Turnover(x) | 0.25 | 0.57 | 0.87 | 0.59 | 1.04 |
| Sales/Fixed Asset(x) | 0.28 | 0.77 | 1.87 | 2.59 | 14.05 |
| Working Capital/Sales(x) | -0.77 | -2.19 | -2.83 | -8.69 | 8.15 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 3.53 | 1.30 | 0.54 | 0.39 | 0.07 |
| Receivable days | 61.40 | 2.66 | 37.69 | 247.35 | 194.00 |
| Inventory Days | 154.12 | 115.80 | 139.46 | 180.65 | 35.26 |
| Payable days | 8.90 | 47.94 | 131.08 | 286.05 | 115.09 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -5.83 | -14.21 | -10.99 | -2.52 | -6.02 |
| Price/Book(x) | -4.16 | -18.98 | 83.21 | 1.23 | 1.08 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 3.53 | 2.38 | 2.50 | 0.24 | 0.69 |
| EV/Core EBITDA(x) | -10.48 | -48.10 | -11.12 | -1.74 | -11.29 |
| EV/EBIT(x) | -10.34 | -45.60 | -10.98 | -1.70 | -10.71 |
| EV/CE(x) | 0.97 | 0.97 | 2.54 | 0.14 | 0.50 |
| M Cap / Sales | 2.15 | 1.55 | 2.30 | 0.38 | 0.40 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -43.09 | -8.14 | 27.68 | -20.10 | 140.37 |
| Core EBITDA Growth(%) | -287.70 | 79.82 | -108.19 | -80.90 | 22.05 |
| EBIT Growth(%) | -272.40 | 78.97 | -105.48 | -76.01 | 22.72 |
| PAT Growth(%) | -90.08 | 51.67 | -77.38 | -76.27 | -35.93 |
| EPS Growth(%) | -90.08 | 51.67 | -77.38 | -76.27 | -35.93 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | -3.05 | -12.18 | 11.56 | 0.15 | 1.05 |
| Current Ratio(x) | 0.38 | 0.65 | 0.53 | 0.92 | 1.12 |
| Quick Ratio(x) | 0.37 | 0.29 | 0.32 | 0.41 | 0.95 |
| Interest Cover(x) | -2.15 | -0.73 | -4.06 | -1.99 | -2.68 |
| Total Debt/Mcap(x) | 0.73 | 0.64 | 0.14 | 0.12 | 0.97 |
Compare Financial Ratios of peers of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION | ₹142.1 Cr | 10.8% | 20.7% | 34% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹364,831.0 Cr | -0.1% | -2.8% | 50.3% | Stock Analytics | |
| CIPLA | ₹113,471.0 Cr | 4.5% | -3.1% | 52.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,713.0 Cr | 4.6% | 1.4% | 22.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,960.0 Cr | 4.7% | 10.8% | 18.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,687.8 Cr | 3.1% | -4.1% | 80.4% | Stock Analytics | |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION | 10.8% |
20.7% |
34% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
